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Background
Therapy of juvenile idiopathic arthritis (JIA) is based on,
among various other treatments, methotrexate (MTX).
Pharmacokinetic data indicate a lower drug resorption
rate when applied orally (po) versus subcutaneous (sc)
administration.
Objectives
We aimed to compare the effects of po and sc applied MTX
on the JIA-disease course.
Methods
According to MTX-administration route, children were
divided into four groups: sc, po, switching from po to sc
and from sc to po. Based on joint counts (pain, swelling
and limited range of motion), patient's and physician's
visual analogue scale for disease activity (VAS) and eryth-
rocyte sedimentation rate (ESR) or C-reactive protein
(CRP), a combined overall disease activity score (entitled
Co-score, CoS) was generated for each patient. Statistically
paired T-test and ANCOVA were applied.
Results
For the sc group, the ESR-CoS improved on average by
2.24 units (CI: 1.57–2.91; p < 0.0001) and the CRP-CoS
by 1.61 units (CI: 0.87–2.35; p < 0.0002). In the po group,
the ESR-CoS improved by 2.37 units (CI: 1.7–3.04; p <
0.0001) and the CRP-CoS by 2.16 units (CI: 1.48–2.85; p
< 0.0001). In the po to sc switcher group, both scores
showed insignificant improvement during the po phase
(p > 0.05). After the change to sc administration, both
scores significantly improved (p < 0.0007 and p < 0.0005
respectively). In the sc to po group, data from only four
patients were analyzable and therefore, statistically irrele-
vant.
Conclusion
Considering data from adult rheumatoid arthritis studies
and MTX pharmacokinetics, our results support to some
extent sc MTX-administration in children, at least at treat-
ment initiation, emphasizing the need of prospective
investigations.
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